levofloxacin has been researched along with prazosin in 19 studies
Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (prazosin) | Trials (prazosin) | Recent Studies (post-2010) (prazosin) |
---|---|---|---|---|---|
4,346 | 581 | 2,209 | 7,914 | 713 | 682 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 9 (47.37) | 29.6817 |
2010's | 10 (52.63) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL | 1 |
Nagashima, R; Nishikawa, T; Tobita, M | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
Giacomini, KM; Huang, Y; Khuri, N; Kido, Y; Kosaka, A; Morrissey, KM; Sali, A; Wittwer, MB; Zhang, X; Zur, AA | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Fugit, RV; Glasheen, JJ; Prochazka, AV | 1 |
Chen, SZ; Chen, TF; Lin, QX; Lin, SG; Liu, XY; Peng, HY; Shan, ZX; Yang, M; Yu, XY; Zhou, SF; Zhou, ZL | 1 |
Chao, WF; Huang, XK; Liang, P; Liu, JW; Wang, L; Wang, QT; Yang, H; Yang, W; Zhou, P | 1 |
Liang, K; Wang, J; Xu, Z; Yan, D | 1 |
Jerončić, A; Papeš, D; Pasini, M | 1 |
Luo, SB; Meng, ZC; Zhang, JY; Zhang, XY | 1 |
1 review(s) available for levofloxacin and prazosin
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 trial(s) available for levofloxacin and prazosin
Article | Year |
---|---|
[Efficacy of compound Xuanju capsule in the treatment of chronic prostatitis with erectile dysfunction].
Topics: Adult; Capsules; Chronic Disease; Drugs, Chinese Herbal; Erectile Dysfunction; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Phytotherapy; Prazosin; Prostatitis; Treatment Outcome; Young Adult | 2012 |
A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Chronic Disease; Drug Therapy, Combination; Humans; Levofloxacin; Male; Pelvic Pain; Prazosin; Prospective Studies; Prostatitis; Syndrome; Treatment Outcome; Urological Agents | 2016 |
[Triple acupuncture at the Qugu acupoint as an adjunctive therapy for type-Ⅲ chronic prostatitis: Analysis of short- and long-term clinical effects].
Topics: Acupuncture Points; Acupuncture Therapy; Anti-Bacterial Agents; Chronic Disease; Chronic Pain; Combined Modality Therapy; Drug Therapy, Combination; Humans; Levofloxacin; Male; Pelvic Pain; Prazosin; Prostatitis; Quality of Life; Recurrence; Syndrome; United States; Urological Agents | 2017 |
15 other study(ies) available for levofloxacin and prazosin
Article | Year |
---|---|
Cheminformatic models to predict binding affinities to human serum albumin.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids | 2001 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
Topics: Computer Simulation; Fluorescent Dyes; Organic Cation Transport Proteins; Prescription Drugs | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
The risk of overanticoagulation with antibiotic use in outpatients on stable warfarin regimens.
Topics: Administration, Oral; Aged; Anti-Infective Agents; Anticoagulants; Azithromycin; Cohort Studies; Drug Interactions; Female; Humans; International Normalized Ratio; Levofloxacin; Male; Ofloxacin; Platelet Aggregation Inhibitors; Prazosin; Retrospective Studies; Trimethoprim, Sulfamethoxazole Drug Combination; Warfarin | 2005 |
A rapid and simple high-performance liquid chromatography method for the determination of human plasma levofloxacin concentration and its application to bioequivalence studies.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Area Under Curve; Biological Availability; Chromatography, High Pressure Liquid; Cross-Over Studies; Humans; Levofloxacin; Male; Ofloxacin; Prazosin; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Specimen Handling; Spectrometry, Fluorescence; Therapeutic Equivalency | 2007 |
Issues in designing a randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome: Comment on Wang et al. Randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/
Topics: Humans; Levofloxacin; Male; Pelvic Pain; Prazosin; Prostatitis | 2017 |